Corbus Pharma (CRBP) Completes Resunab Phase 2 in Systemic Sclerosis
Tweet Send to a Friend
Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) announced that it has completed the Phase 2 study evaluating Resunab for the treatment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
